• +1-646-491-9876
    • +91-20-67278686

    Search

    Depression - Pipeline Review, H1 2017

    Depression - Pipeline Review, H1 2017

    • Report Code ID: RW0001767498
    • Category Pharmaceuticals
    • No. of Pages 476
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Depression - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2017, provides an overview of the Depression (Central Nervous System) pipeline landscape.

    Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 14, 27, 23, 74, 15 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 17 and 8 molecules, respectively.

    Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 7
    Depression - Overview 8
    Depression - Therapeutics Development 9
    Depression - Therapeutics Assessment 33
    Depression - Companies Involved in Therapeutics Development 49
    Depression - Drug Profiles 97
    Depression - Dormant Projects 427
    Depression - Discontinued Products 441
    Depression - Product Development Milestones 446
    Appendix 456

    List of Tables

    Number of Products under Development for Depression, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Depression - Pipeline by 4D Pharma PLC, H1 2017
    Depression - Pipeline by AB Science SA, H1 2017
    Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Adamed Sp z oo, H1 2017
    Depression - Pipeline by Addex Therapeutics Ltd, H1 2017
    Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Alkermes Plc, H1 2017
    Depression - Pipeline by Allergan Plc, H1 2017
    Depression - Pipeline by Alvogen Korea Co Ltd, H1 2017
    Depression - Pipeline by Amorsa Therapeutics Inc, H1 2017
    Depression - Pipeline by Anavex Life Sciences Corp, H1 2017
    Depression - Pipeline by Angelini Group, H1 2017
    Depression - Pipeline by Angita BV, H1 2017
    Depression - Pipeline by Araim Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by AstraZeneca Plc, H1 2017
    Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Axsome Therapeutics Inc, H1 2017
    Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by BioCrea GmbH, H1 2017
    Depression - Pipeline by BioLite Inc, H1 2017
    Depression - Pipeline by Bionomics Ltd, H1 2017
    Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Depression - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Depression - Pipeline by Calico LLC, H1 2017
    Depression - Pipeline by Celgene Corp, H1 2017
    Depression - Pipeline by Celon Pharma SA, H1 2017
    Depression - Pipeline by Cerecor Inc, H1 2017
    Depression - Pipeline by Clera Inc, H1 2017
    Depression - Pipeline by Delpor Inc, H1 2017
    Depression - Pipeline by Domain Therapeutics SA, H1 2017
    Depression - Pipeline by Eisai Co Ltd, H1 2017
    Depression - Pipeline by Eli Lilly and Company, H1 2017
    Depression - Pipeline by Evotec AG, H1 2017
    Depression - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by FPRT Bio Inc, H1 2017
    Depression - Pipeline by GlaxoSmithKline Plc, H1 2017
    Depression - Pipeline by GliaCure Inc, H1 2017
    Depression - Pipeline by H. Lundbeck A/S, H1 2017
    Depression - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Depression - Pipeline by Hua Medicine (Shanghai) Ltd, H1 2017
    Depression - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
    Depression - Pipeline by Impel NeuroPharma Inc, H1 2017
    Depression - Pipeline by INSYS Therapeutics Inc, H1 2017
    Depression - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
    Depression - Pipeline by Intra-Cellular Therapies Inc, H1 2017
    Depression - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Johnson & Johnson, H1 2017
    Depression - Pipeline by KemPharm Inc, H1 2017
    Depression - Pipeline by Lead Discovery Center GmbH, H1 2017
    Depression - Pipeline by Les Laboratoires Servier SAS, H1 2017
    Depression - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
    Depression - Pipeline by Luye Pharma Group Ltd, H1 2017
    Depression - Pipeline by Mapi Pharma Ltd, H1 2017
    Depression - Pipeline by Mapreg SAS, H1 2017
    Depression - Pipeline by Medlab Clinical Ltd, H1 2017
    Depression - Pipeline by Meta-IQ ApS, H1 2017
    Depression - Pipeline by Methylation Sciences Inc, H1 2017
    Depression - Pipeline by miCure Therapeutics Ltd, H1 2017
    Depression - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Depression - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
    Depression - Pipeline by Neuralstem Inc, H1 2017
    Depression - Pipeline by Neurocrine Biosciences Inc, H1 2017
    Depression - Pipeline by NeuroNascent Inc, H1 2017
    Depression - Pipeline by NeurOp Inc, H1 2017
    Depression - Pipeline by Newron Pharmaceuticals SpA, H1 2017
    Depression - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
    Depression - Pipeline by nLife Therapeutics SL, H1 2017
    Depression - Pipeline by Omeros Corp, H1 2017
    Depression - Pipeline by Orexigen Therapeutics Inc, H1 2017
    Depression - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Depression - Pipeline by Pfizer Inc, H1 2017
    Depression - Pipeline by Pherin Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Polleo Pharma Ltd, H1 2017
    Depression - Pipeline by Protagenic Therapeutics Inc, H1 2017
    Depression - Pipeline by Relmada Therapeutics Inc, H1 2017
    Depression - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Richter Gedeon Nyrt, H1 2017
    Depression - Pipeline by Sage Therapeutics Inc, H1 2017
    Depression - Pipeline by Saniona AB, H1 2017
    Depression - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
    Depression - Pipeline by Sound Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Depression - Pipeline by Supernus Pharmaceuticals Inc, H1 2017
    Depression - Pipeline by Suven Life Sciences Ltd, H1 2017
    Depression - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
    Depression - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Depression - Pipeline by Tetra Discovery Partners LLC, H1 2017
    Depression - Pipeline by Trevena Inc, H1 2017
    Depression - Pipeline by TRImaran Pharma Inc, H1 2017
    Depression - Pipeline by VistaGen Therapeutics Inc, H1 2017
    Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co Ltd, H1 2017
    Depression - Pipeline by Zogenix Inc, H1 2017
    Depression - Pipeline by Zysis Ltd, H1 2017
    Depression - Dormant Projects, H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..9) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..10) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..11) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..12) , H1 2017
    Depression - Dormant Projects, H1 2017 (Contd..13) , H1 2017
    Depression - Discontinued Products, H1 2017
    Depression - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Depression - Discontinued Products, H1 2017 (Contd..2) , H1 2017
    Depression - Discontinued Products, H1 2017 (Contd..3) , H1 2017
    Depression - Discontinued Products, H1 2017 (Contd..4) , H1 2017

    List of Figures

    Number of Products under Development for Depression, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    4D Pharma PLC
    AB Science SA
    Acadia Pharmaceuticals Inc
    Adamed Sp z oo
    Addex Therapeutics Ltd
    Aequus Pharmaceuticals Inc
    Alkermes Plc
    Allergan Plc
    Alvogen Korea Co Ltd
    Amorsa Therapeutics Inc
    Anavex Life Sciences Corp
    Angelini Group
    Angita BV
    Araim Pharmaceuticals Inc
    AstraZeneca Plc
    Avanir Pharmaceuticals Inc
    Axsome Therapeutics Inc
    Azevan Pharmaceuticals Inc
    BioCrea GmbH
    BioLite Inc
    Bionomics Ltd
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Calico LLC
    Celgene Corp
    Celon Pharma SA
    Cerecor Inc
    Clera Inc
    Delpor Inc
    Domain Therapeutics SA
    Eisai Co Ltd
    Eli Lilly and Company
    Evotec AG
    F. Hoffmann-La Roche Ltd
    Fabre-Kramer Pharmaceuticals Inc
    FPRT Bio Inc
    GlaxoSmithKline Plc
    GliaCure Inc
    H. Lundbeck A/S
    Heptares Therapeutics Ltd
    Hua Medicine (Shanghai) Ltd
    Hyundai Pharmaceutical Co Ltd
    Impel NeuroPharma Inc
    INSYS Therapeutics Inc
    Intas Pharmaceuticals Ltd
    Intra-Cellular Therapies Inc
    INVENT Pharmaceuticals Inc
    Johnson & Johnson
    KemPharm Inc
    Lead Discovery Center GmbH
    Les Laboratoires Servier SAS
    Lixte Biotechnology Holdings Inc
    Luye Pharma Group Ltd
    Mapi Pharma Ltd
    Mapreg SAS
    Medlab Clinical Ltd
    Meta-IQ ApS
    Methylation Sciences Inc
    miCure Therapeutics Ltd
    Mitsubishi Tanabe Pharma Corp
    Navya Biologicals Pvt Ltd
    Neuralstem Inc
    Neurocrine Biosciences Inc
    NeuroNascent Inc
    NeurOp Inc
    Newron Pharmaceuticals SpA
    Nippon Chemiphar Co Ltd
    nLife Therapeutics SL
    Omeros Corp
    Orexigen Therapeutics Inc
    Otsuka Holdings Co Ltd
    Pfizer Inc
    Pherin Pharmaceuticals Inc
    Polleo Pharma Ltd
    Protagenic Therapeutics Inc
    Relmada Therapeutics Inc
    Reviva Pharmaceuticals Inc
    Richter Gedeon Nyrt
    Sage Therapeutics Inc
    Saniona AB
    SK Biopharmaceuticals Co Ltd
    Sound Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Supernus Pharmaceuticals Inc
    Suven Life Sciences Ltd
    Taisho Pharmaceutical Holdings Co Ltd
    Takeda Pharmaceutical Company Ltd
    Tetra Discovery Partners LLC
    Trevena Inc
    TRImaran Pharma Inc
    VistaGen Therapeutics Inc
    Zhejiang Huahai Pharmaceutical Co Ltd
    Zogenix Inc
    Zysis Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//depression-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//depression-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//depression-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments